

# Hareth Nahi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9436894/publications.pdf>

Version: 2024-02-01

201  
papers

9,302  
citations

71102

41  
h-index

43889

91  
g-index

204  
all docs

204  
docs citations

204  
times ranked

8524  
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 1319-1331.	27.0	1,210
2	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 1207-1219.	27.0	948
3	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	10.7	695
4	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	27.0	684
5	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , 2016, 128, 37-44.	1.4	347
6	Teclistamab in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 495-505.	27.0	291
7	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. <i>Leukemia</i> , 2017, 31, 2443-2448.	7.2	259
8	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	10.7	254
9	Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. <i>Blood</i> , 2008, 111, 3155-3162.	1.4	171
10	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematology</i> , the, 2020, 7, e370-e380.	4.6	170
11	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
12	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. <i>Nature Communications</i> , 2016, 7, 12050.	12.8	146
13	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1582-1596.	10.7	141
14	Teclistamab, a B-cell maturation antigen-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. <i>Lancet</i> , The, 2021, 398, 665-674.	13.7	138
15	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
16	Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. <i>Blood</i> , 2013, 121, 4647-4654.	1.4	128
17	Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. <i>Leukemia</i> , 2010, 24, 932-941.	7.2	113
18	Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. <i>Cytotherapy</i> , 2010, 12, 1044-1055.	0.7	112

#	ARTICLE	IF	CITATIONS
19	Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. <i>Haematologica</i> , 2018, 103, 506-513.	3.5	103
20	Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. <i>British Journal of Haematology</i> , 2005, 130, 96-98.	2.5	101
21	Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. <i>Nature Communications</i> , 2015, 6, 7213.	12.8	101
22	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	3.7	90
23	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. <i>Blood</i> , 2019, 134, 668-677.	1.4	87
24	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. <i>Nature Communications</i> , 2018, 9, 3707.	12.8	86
25	Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. <i>PLoS ONE</i> , 2019, 14, e0211927.	2.5	85
26	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	4.1	83
27	Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma. <i>Blood</i> , 2018, 131, 2138-2150.	1.4	77
28	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , 2020, 7, e447-e455.	4.6	74
29	Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. <i>Blood</i> , 2011, 118, 5573-5582.	1.4	67
30	Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. <i>Haematologica</i> , 2023, 108, 890-897.	3.5	65
31	APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. <i>European Journal of Haematology</i> , 2011, 86, 206-215.	2.2	61
32	Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study. <i>Blood</i> , 2012, 120, 73-73.	1.4	60
33	PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. <i>British Journal of Haematology</i> , 2006, 132, 230-236.	2.5	57
34	Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. <i>British Journal of Haematology</i> , 2006, 135, 367-373.	2.5	56
35	Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. <i>British Journal of Haematology</i> , 2004, 127, 285-291.	2.5	53
36	Mutated and non-mutated TP53 as targets in the treatment of leukaemia. <i>British Journal of Haematology</i> , 2008, 141, 445-453.	2.5	51

#	ARTICLE	IF	CITATIONS
37	Updated Phase I Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 27-27.	1.4	51
38	The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment. <i>PLoS ONE</i> , 2014, 9, e101819.	2.5	49
39	Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. <i>European Journal of Haematology</i> , 2017, 99, 216-222.	2.2	48
40	EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. <i>Oncotarget</i> , 2017, 8, 10213-10224.	1.8	47
41	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	4.1	45
42	Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. <i>European Journal of Haematology</i> , 2012, 88, 485-496.	2.2	42
43	A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 2730-2736.	7.0	41
44	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. <i>Leukemia</i> , 2022, 36, 1066-1077.	7.2	39
45	Association of ABCB1 polymorphisms with survival and in vitro cytotoxicity in de novo acute myeloid leukemia with normal karyotype. <i>Pharmacogenomics Journal</i> , 2012, 12, 111-118.	2.0	38
46	Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population. <i>British Journal of Haematology</i> , 2014, 164, 684-693.	2.5	38
47	Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 100-100.	1.6	37
48	Clinical impact of chromosomal aberrations in multiple myeloma. <i>Journal of Internal Medicine</i> , 2011, 269, 137-147.	6.0	35
49	Proteasome inhibitors and iDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. <i>European Journal of Haematology</i> , 2016, 96, 46-54.	2.2	35
50	Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 808-812.	2.4	34
51	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , 2016, 76, 853-867.	10.9	34
52	The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 439-448.	2.3	32
53	Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation. <i>Medical Oncology</i> , 2012, 29, 1231-1236.	2.5	32
54	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). <i>Blood</i> , 2018, 132, LBA-2-LBA-2.	1.4	30

#	ARTICLE	IF	CITATIONS
55	Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 508-516.	1.3	29
56	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 896-896.	1.4	29
57	Decreased survival in normal karyotype AML with single nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5-aminopyrimidinase. <i>American Journal of Hematology</i> , 2013, 88, 1001-1006.	4.1	28
58	Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone. <i>Blood</i> , 2016, 128, 246-246.	1.4	28
59	Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. <i>Oncologist</i> , 2011, 16, 388-403.	3.7	26
60	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. <i>Blood</i> , 2019, 134, 1875-1875.	1.4	26
61	All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>European Journal of Cancer</i> , 2019, 106, 89-98.	2.8	25
62	Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). <i>Haematologica</i> , 2021, 106, 1725-1732.	3.5	25
63	Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?. <i>European Journal of Haematology</i> , 2019, 103, 588-596.	2.2	24
64	The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression. <i>Nature Communications</i> , 2018, 9, 1649.	12.8	22
65	Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 227-237.	1.6	22
66	Acquired hemophagocytic lymphohistiocytosis associated with multiple myeloma. <i>Medical Oncology</i> , 2011, 28, 539-543.	2.5	21
67	Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	2.5	21
68	Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells. <i>Cancers</i> , 2019, 11, 69.	3.7	21
69	Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery. <i>Medical Oncology</i> , 2012, 29, 2191-2199.	2.5	20
70	Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO). <i>Blood</i> , 2016, 128, 1149-1149.	1.4	20
71	Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. <i>Cell Reports Medicine</i> , 2022, 3, 100508.	6.5	20
72	Re-challenging with anti-CD38 monotherapy in triple refractory multiple myeloma patients is a feasible and safe approach. <i>British Journal of Haematology</i> , 2016, 174, 473-477.	2.5	19

#	ARTICLE	IF	CITATIONS
73	Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial.. <i>Blood</i> , 2009, 114, 530-530.	1.4	19
74	Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study. <i>Blood</i> , 2017, 130, 838-838.	1.4	19
75	Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8513-8513.	1.6	19
76	The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. <i>Oncotarget</i> , 2017, 8, 103731-103743.	1.8	19
77	Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. <i>Haematologica</i> , 2022, 107, 2408-2417.	3.5	19
78	Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. <i>Leukemia</i> , 2017, 31, 2435-2442.	7.2	18
79	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. <i>Haematologica</i> , 2019, 104, 2358-2360.	3.5	18
80	An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients. <i>Haematologica</i> , 2008, 93, 1734-1738.	3.5	17
81	Case Report: Treatment of light chain amyloidosis with daratumumab monotherapy in two patients. <i>European Journal of Haematology</i> , 2018, 100, 386-388.	2.2	17
82	Outcome of COVID-19 in multiple myeloma patients in relation to treatment. <i>European Journal of Haematology</i> , 2020, 105, 751-754.	2.2	17
83	Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 619-631.	2.5	17
84	The prognostic significance of 8p21 deletion in multiple myeloma. <i>British Journal of Haematology</i> , 2009, 144, 266-268.	2.5	16
85	Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009. <i>Bone Marrow Transplantation</i> , 2016, 51, 1569-1572.	2.4	16
86	Health resource utilization associated with skeletal-related events: results from a retrospective European study. <i>European Journal of Health Economics</i> , 2016, 17, 711-721.	2.8	16
87	Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 183-193.	2.3	16
88	Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070). <i>Blood</i> , 2015, 126, 26-26.	1.4	16
89	Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement. <i>European Journal of Haematology</i> , 2014, 92, 454-455.	2.2	15
90	Direct evidence for a polygenic etiology in familial multiple myeloma. <i>Blood Advances</i> , 2017, 1, 619-623.	5.2	15

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.. Journal of Clinical Oncology, 2019, 37, 8005-8005.	1.6	15
92	Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. Acta Oncol <sup>3</sup> gica, 2016, 55, 554-560.	1.8	14
93	Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) <b>—</b> CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).. Journal of Clinical Oncology, 2021, 39, 8007-8007.	1.6	14
94	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update. Blood, 2019, 134, 1865-1865.	1.4	14
95	Impact of <i><sc>ABC</sc>1</i> single nucleotide polymorphisms 1236C<sup>&gt;T and 2677G<sup>&gt;T on overall survival in <i><sc>FLT</sc>3</i> wild<sup>€</sup>type <i>de novo</i> <sc>AML</sc> patients with normal karyotype. British Journal of Haematology, 2014, 167, 671-680.	2.5	13
96	<i><sc>TP</sc>53</i> mutations and <i>MDM2</i><sup>SNP309</sup> identify subgroups of <sc>AML</sc> patients with impaired outcome. European Journal of Haematology, 2015, 94, 355-362.	2.2	13
97	Multiple myeloma in patients up to 30Âyears of age: a multicenter retrospective study of 52 cases. Leukemia and Lymphoma, 2019, 60, 471-476.	1.3	13
98	Effects of singleâ€agent bortezomib as postâ€transplant consolidation therapy on multiple myelomaâ€related bone disease: a randomized phase <sc>II</sc> study. British Journal of Haematology, 2017, 178, 61-71.	2.5	12
99	Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor. Bone Marrow Transplantation, 2020, 55, 356-366.	2.4	12
100	Exposureâ€Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. Journal of Clinical Pharmacology, 2021, 61, 614-627.	2.0	12
101	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leukemia and Lymphoma, 2019, 60, 163-171.	1.3	11
102	Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. European Journal of Haematology, 2019, 103, 247-254.	2.2	11
103	A genealogical and clinical study of the phenotypical variation within the Swedish transthyretin His88Arg (p. His108Arg) amyloidosis family. European Journal of Medical Genetics, 2015, 58, 211-215.	1.3	10
104	Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Realâ€life outcomes of daratumumab treatment. European Journal of Haematology, 2020, 105, 196-202.	2.2	10
105	Treosulfan conditioning for allogeneic transplantation in multiple myeloma â€ improved overall survival in first line haematopoietic stem cell transplantation â€ a large retrospective study by the Chronic Malignancies Working Party of the EBMT. British Journal of Haematology, 2020, 189, e213-e217.	2.5	10
106	Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group. European Journal of Haematology, 2022, 108, 34-44.	2.2	10
107	A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor. Biology of Blood and Marrow Transplantation, 2019, 25, 34-40.	2.0	9
108	Outcome and characteristics of nonâ€measurable myeloma: A cohort study with populationâ€based data from the Swedish Myeloma Registry. European Journal of Haematology, 2020, 104, 376-382.	2.2	8

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO). <i>Blood</i> , 2018, 132, 2006-2006.	1.4	8
110	Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation. <i>Oncology Reports</i> , 2009, 22, 137-42.	2.6	7
111	Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis. <i>Acta Haematologica</i> , 2020, 143, 500-503.	1.4	7
112	Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). <i>American Journal of Hematology</i> , 2021, 96, 925-933.	4.1	7
113	Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy. <i>American Journal of Hematology</i> , 2021, 96, E443-E446.	4.1	7
114	Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 29-29.	1.4	7
115	Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. <i>PLoS ONE</i> , 2015, 10, e0138248.	2.5	7
116	Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study. <i>Annals of Hematology</i> , 2021, 100, 1065-1077.	1.8	6
117	Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO). <i>Journal of Clinical Oncology</i> , 2018, 36, 8013-8013.	1.6	6
118	Expression of p14ARF in De Novo AML with Normal Karyotype. Implication on Drug Resistance and Survival. <i>Blood</i> , 2007, 110, 4261-4261.	1.4	6
119	Transmission of chronic lymphocytic leukaemia from a blood stem cell sibling donor to the recipient. <i>British Journal of Haematology</i> , 2008, 143, 751-753.	2.5	5
120	A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis. <i>Acta Haematologica</i> , 2013, 130, 7-15.	1.4	5
121	Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma. <i>Value in Health</i> , 2017, 20, A408.	0.3	5
122	Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. <i>American Journal of Hematology</i> , 2021, 96, E63-E65.	4.1	5
123	Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder. <i>Blood</i> , 2021, 137, 1260-1263.	1.4	5
124	Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 23-30.	4.1	5
125	A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group. <i>Blood</i> , 2019, 134, 601-601.	1.4	5
126	Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba. <i>Blood</i> , 2019, 134, 1906-1906.	1.4	5



#	ARTICLE	IF	CITATIONS
127	Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival. <i>Leukemia and Lymphoma</i> , 2009, 50, 1512-1518.	1.3	4
128	Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma – a retrospective population based study of 1162 patients. <i>European Journal of Haematology</i> , 2014, 92, 19-25.	2.2	4
129	Involved free light chain: an early independent predictor of response and progression in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2227-2234.	1.3	4
130	Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients. <i>Blood</i> , 2020, 136, 20-20.	1.4	4
131	A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 40-41.	1.4	4
132	Real World Data In Myeloma: Experiences From The Swedish Population-Based Registry On 2494 Myeloma Patients Diagnosed 2008-2011. <i>Blood</i> , 2013, 122, 1972-1972.	1.4	4
133	Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8025-8025.	1.6	4
134	Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8058-TPS8058.	1.6	4
135	Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8035-8035.	1.6	4
136	Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 258.e1-258.e8.	1.2	4
137	Constitutional inv(3) in myelodysplastic syndromes. <i>Leukemia Research</i> , 2010, 34, 1627-1629.	0.8	3
138	Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution. <i>Medical Oncology</i> , 2012, 29, 2348-2358.	2.5	3
139	Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017. <i>Blood</i> , 2019, 134, 4575-4575.	1.4	3
140	An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S333-S334.	0.4	2
141	Greater Treatment Satisfaction in Patients Receiving Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) for Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e247-e248.	0.4	2
142	Predicting Drug Resistance by Single-Cell RNASeq in Patients with Multiple Myeloma. <i>Clinical Chemistry</i> , 2021, 67, 1309-1311.	3.2	2
143	A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data. <i>Blood</i> , 2011, 118, 1873-1873.	1.4	2
144	An open-label, dose-escalation phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8071-TPS8071.	1.6	2

#	ARTICLE	IF	CITATIONS
145	Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2018, 132, 2143-2143.	1.4	2
146	Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 1-2.	1.4	2
147	Topoisomerase III $\pm$ mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia. <i>International Journal of Oncology</i> , 2007, , .	3.3	1
148	In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on Gmid $\text{\textcircled{c}}$ one et al. <i>Medical Oncology</i> , 2013, 30, 569.	2.5	1
149	Lenalidomide versus lenalidomide $\hat{+}$ $\hat{+}$ dexamethasone prolonged treatment after second $\hat{+}$ line lenalidomide $\hat{+}$ $\hat{+}$ dexamethasone induction in multiple myeloma. <i>Cancer Medicine</i> , 2018, 7, 2256-2268.	2.8	1
150	S1602. CARFILZOMIB AND DEXAMETHASONE MAINTENANCE PROLONG TIME TO PROGRESSION. <i>HemaSphere</i> , 2019, 3, 737-738.	2.7	1
151	Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups. <i>European Journal of Haematology</i> , 2021, 106, 546-554.	2.2	1
152	Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti $\hat{+}$ myeloma treatment. <i>International Journal of Dermatology</i> , 2021, 60, e271-e273.	1.0	1
153	MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S424-S425.	0.4	1
154	A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines. <i>Blood</i> , 2018, 132, 1975-1975.	1.4	1
155	Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population.. <i>Blood</i> , 2012, 120, 2970-2970.	1.4	1
156	Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial. <i>Blood</i> , 2014, 124, 3458-3458.	1.4	1
157	The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex. <i>Blood</i> , 2015, 126, 3047-3047.	1.4	1
158	Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8537-8537.	1.6	1
159	Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2016, 128, 2266-2266.	1.4	1
160	Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO). <i>Blood</i> , 2018, 132, 1995-1995.	1.4	1
161	Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study. <i>Blood</i> , 2021, 138, 1667-1667.	1.4	1
162	Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose. <i>Blood</i> , 2021, 138, 1646-1646.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study. <i>Cancer Reports</i> , 2022, 5, e1614.	1.4	1
164	Comparative Real World Effectiveness of Novel Agents Versus Conventional Therapies in Multiple Myeloma Patients in Sweden. <i>Value in Health</i> , 2014, 17, A545-A546.	0.3	0
165	Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT). <i>Value in Health</i> , 2014, 17, A617-A618.	0.3	0
166	Bortezomib Re-treatment in Patients with Multiple Myeloma (MM). A Real World Medical Practice Experience from a Swedish National Registry. <i>Value in Health</i> , 2014, 17, A617.	0.3	0
167	Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e225-e226.	0.4	0
168	Novel RNA construct increases cytotoxic proteins in lymphocytes and leads to prolonged survival in an experimental syngeneic immunocompetent Multiple Myeloma model. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e170.	0.4	0
169	Reinstating anti-tumor activity of Natural Killer cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e158.	0.4	0
170	Over 10 years relative median survival in MM patients ≥ 65 years with VGPR or better on 1st line treatment. Population-based data on patients diagnosed 2008-2018 from the Swedish Myeloma Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e209.	0.4	0
171	PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA. <i>HemaSphere</i> , 2019, 3, 248-249.	2.7	0
172	A phase 2 study of carfilzomib plus elotuzumab plus dexamethasone for myeloma patients relapsed after 1-3 prior treatment lines. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e279-e280.	0.4	0
173	Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma – Improved Overall Survival in first line Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e206.	0.4	0
174	Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden. <i>Acta Haematologica</i> , 2021, 144, 519-527.	1.4	0
175	Poster: MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S252.	0.4	0
176	RITA Activates p53 Function in Chronic Lymphocytic Leukaemia Cells and Induces Apoptosis. <i>Blood</i> , 2005, 106, 5536-5536.	1.4	0
177	Low Expression of p14ARF in De Novo AML with Normal Karyotype Is Associated with Short Survival but Increased In Vitro Sensitivity to p53 Modulating Drugs. <i>Blood</i> , 2008, 112, 2937-2937.	1.4	0
178	Impact of Chromosome 13 Deletion and Plasma Cell Load on Long-Term Survival of Patients with Multiple Myeloma Undergoing Autologous Transplantation. <i>Blood</i> , 2008, 112, 5148-5148.	1.4	0
179	Do Deletions in 9p Reflect Prognosis in Adult Precursor B-Cell ALL? a Multi-Centre Study of 381 Patients. <i>Blood</i> , 2008, 112, 4865-4865.	1.4	0
180	The Prognostic Significance of 8p21 Deletion in Multiple Myeloma. <i>Blood</i> , 2008, 112, 5153-5153.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS.. Blood, 2008, 112, 3337-3337.	1.4	0
182	Implications On Drug Resistance and Survival of ABCB1 Single Nucleotide Polymorphisms in Normal Karyotype De Novo AML.. Blood, 2009, 114, 2648-2648.	1.4	0
183	In Vitro and Ex Vivo Studies On Cell Lines and Primary Human Leukemia Cells of the Effects of APR-246 Alone and in Combination with Conventional Chemotherapeutic Drugs.. Blood, 2009, 114, 2751-2751.	1.4	0
184	Abstract 2757: NT5C2 single nucleotide polymorphisms affects survival and response inde novoAML patients with normal karyotype. , 2010, , .		0
185	Global and HOX Gene DNA Methylation In Normal Karyotype Acute Myeloid Leukemia: Clinical Implications and Molecular Correlations. Blood, 2010, 116, 231-231.	1.4	0
186	Follow-up of Real Life Treated Multiple Myeloma Patients: Response, Disease Progression and Overall Survival,. Blood, 2011, 118, 3937-3937.	1.4	0
187	Is Renal Impairment Still a Poor Prognostic Marker in Myeloma Care?: A Population Based Study Including 1542 Patients. Blood, 2012, 120, 5033-5033.	1.4	0
188	Abstract 1170: Correlation between cytidine deaminase single nucleotide polymorphisms andin vitrodrug sensitivity, DNA methylation and outcome in normal karyotype acute myelogenous leukemia.. , 2013, , .		0
189	Re-Challenging with Anti-CD38 Monotherapy in Triple-Refractory Multiple Myeloma Patients Is a Feasible and Safe Approach. Blood, 2015, 126, 5366-5366.	1.4	0
190	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	1.4	0
191	Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol. Blood, 2016, 128, 5692-5692.	1.4	0
192	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Blood, 2016, 128, 4414-4414.	1.4	0
193	Abstract 5030: The impact ofABCB1single nucleotide polymorphisms on the outcome in lenalidomide treated multiple myeloma patients. , 2017, , .		0
194	Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma Improved Overall Survival in Upfront Hematopoietic Stem Cell Transplantation â€” a Large Retrospective Study By the Chronic Malignancies Working Party of the EBMT. Blood, 2018, 132, 3464-3464.	1.4	0
195	Long-Lasting Remissions for Myeloma Patients on Daratumumab Therapy from the GEN501 and GEN503 Trials. Blood, 2018, 132, 3308-3308.	1.4	0
196	Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis. Blood, 2019, 134, 3151-3151.	1.4	0
197	OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S1.	0.4	0
198	CD38 Down-Regulation on Ex Vivo Activated and Expanded NK Cells for Cell Therapy Persists after Infusion. Blood, 2021, 138, 4796-4796.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial. <i>Blood</i> , 2021, 138, 1655-1655.	1.4	0
200	Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA. <i>Blood</i> , 2021, 138, 4095-4095.	1.4	0
201	P-184: Regional differences in treatment and outcome for myeloma patients in Sweden: a population based Swedish Myeloma Register study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S138.	0.4	0